Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taxotere and Gemcitabine for Recurrent NSCLC
NCT00278460Phase 2Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- Nov 2000
- Primary completion
- Feb 2006
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of docetaxel and gemcitabine in non-small cell lung cancer (NSCLC), sponsored by Wake Forest University Health Sciences. Primary endpoints: Objective Response Rate at 6 weeks, Overall Survival and 2 more. Started Nov 2000; status: completed.
02
Drugs
docetaxelgemcitabine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00278460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00278460.